Pfizer Poised for Political Play in Novo Nordisk's Bid Showdown

Pfizer is considering leveraging its connections within the Trump administration to counter Novo Nordisk's bid to acquire U.S. obesity biotech firm Metsera. As Novo challenges Pfizer's initial agreement, Pfizer faces strategic decisions, antitrust concerns, and financial implications to retain its competitive edge.

In a brewing corporate clash, U.S. pharmaceutical giant Pfizer might use its influential ties with the Trump administration to counter a surprise rival bid from Novo Nordisk. Novo's move to acquire the U.S. obesity biotech firm Metsera has surprised many, overshadowing Pfizer’s previous deal.

Competition experts predict a market soar to $150 billion in the coming years, intensifying the stakes. Pfizer now has four days to respond to Novo's superior bid. Political connections may play a pivotal role, with Pfizer's CEO Albert Bourla having nurtured a close relationship with President Trump.

Pfizer's challenge extends beyond political dynamics, tackling antitrust concerns and its own track record of missteps in the obesity market. The company faces pressure not to overbid, potentially exacerbating already existing financial strains.